At this year’s CPhI Worldwide congress in Madrid, Spain, Archer Daniels Midland Company (ADM) will present its range of products spanning probiotics and microbiome solutions to highly purified, injectable-grade vegetable oils.
At this year’s CPhI Worldwide congress in Madrid, Spain, Archer Daniels Midland Company (ADM) will present its range of products spanning probiotics and microbiome solutions to highly purified, injectable-grade vegetable oils.
Visitors to booth 8C122 will be able to view the company's bioactive portfolio as well as the pharmaceutical-grade purified vegetables oils for use as APIs and excipients in injectable, oral, or topical formulations from ADM SIO. Innovative concepts to be showcased during the event include probiotic sticks and probiotic capsules.
Additionally, there will be research data assessing the potential of these probiotics in the treatment and prevention of atopic dermatitis and mild to moderate psoriasis-as well as for use in weight management-accessible at the booth and may be discussed further with ADM Biopolis staff.
“Our world-class R&D team continues to explore future applications for our microbial technologies in line with increased demand for innovation and personalized nutrition solutions,” explained Daniel Ramon Calvo, marketing and communications manager, ADM Biopolis, in a press release. “Now as ADM, we have expertise across all stages of product development. This in-depth knowledge means we can support both pharmaceutical and food supplement customers in creating the next generation microbiome and biotech-based products for better living. We are, for instance, specialists in microbial strain and bioprocess design and development through cell factories.”
“Excipients are used in all drug formulations and are essential for product manufacturing and performance. We take advantage of our purification and analytical expertise to offer highly purified oils from vegetable origins, produced in our cGMP workshops, and compliant with the latest requirements from the main health authorities,” added Hervé Sibillat, general manager, ADM SIO, in the same press release.
Source: ADM
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.